Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
183
-
Total 13F shares, excl. options
-
105M
-
Shares change
-
-15.9M
-
Total reported value, excl. options
-
$1.06B
-
Value change
-
-$142M
-
Put/Call ratio
-
0.7
-
Number of buys
-
96
-
Number of sells
-
-101
-
Price
-
$10.17
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q1 2021
238 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q1 2021.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 183 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 105M shares
of 210M outstanding shares and own 49.87% of the company stock.
Largest 10 shareholders include BlackRock Inc. (16.2M shares), BAKER BROS. ADVISORS LP (12.7M shares), VANGUARD GROUP INC (9.7M shares), Sarissa Capital Management LP (7.64M shares), STATE STREET CORP (7.31M shares), HealthCor Management, L.P. (4.89M shares), Artisan Partners Limited Partnership (3.03M shares), GEODE CAPITAL MANAGEMENT, LLC (2.99M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.61M shares), and Nuveen Asset Management, LLC (2.5M shares).
This table shows the top 183 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.